A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of MK0634 in Postmenopausal Women With Overactive Bladder
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2014
At a glance
- Drugs MK 0634 (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms COMPLETED
- Sponsors Merck & Co
- 05 Oct 2011 Official Title amended as reported by ClinicalTrials.gov.
- 05 Oct 2011 Actual end date (September 2009) added as reported by ClinicalTrials.gov.
- 05 Oct 2011 Primary endpoint identified as reported by ClinicalTrials.gov.